Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

When putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics LENZ now meets that criteria, with a jump from 79 to 85 Friday. Please watch the video at ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

LENZ Therapeutics' LNZ100 leads presbyopia treatment with superior efficacy and FDA approval likely by Aug. 2025. Learn more ...

Rating for LENZ TherapeuticsLENZ climbed into a new percentile Wednesday, with a rise from 69 to 82.Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental Portfolio ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 Provided by GlobeNewswire Mar 11, 2025, 12:00:00 PM ...

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients ...

LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. have entered into an exclusive licensing and commercialization agreement for LNZ100, an aceclidine-based eye drop intended to treat ...